Company Overview - Medtronic PLC is the largest medtech company globally by revenue, with a history of innovation and market leadership since the 1940s [3] - The company's revenue segments include Cardiology (37%), Neuroscience (29%), Medical Surgical (25%), and Other (9%) [3] Stock Performance - Medtronic's stock price has appreciated only 15% over the past decade and has decreased by 8% in the last five years, indicating long-term investor frustration [4] - The company has delivered mid-single digit revenue growth for the past 10 years, which has been underwhelming compared to peers [4] Strategic Changes - Following engagement with Elliott Investment Management, Medtronic appointed John Groetelaars and Bill Jellison to its board and formed a Growth Committee and an Operating Committee [2][5] - The Growth Committee will focus on portfolio management, identifying tuck-in M&A opportunities, and reviewing existing business inefficiencies [5] - The Operating Committee aims to address margin challenges and improve gross margin expansion, which has eroded approximately 500 basis points since the Covid-19 pandemic [6] Future Growth Prospects - Medtronic plans to spin off its diabetes business within the next 15 months to concentrate on core operations [7] - Two product developments, PulseSelect and Symplicity Spyral, are expected to contribute significantly to long-term growth [7] Activist Engagement - Elliott Investment Management has successfully completed the activist phase of its engagement and is now focused on the business turnaround [8] - The addition of directors with extensive medtech experience is aimed at enhancing the company's strategic direction [8]